Combined modality therapy improves overall survival for angiosarcoma

References

• Mastrangelo G, Coindre JM, Ducimetiere F, et al. Incidence of soft tissue sarcoma and beyond: a population-based prospective study in 3 European regions. Cancer. 2012;118:5339–5348.
   PubMed Web of Science ®Google Scholar
• Rouhani P, Fletcher CD, Devesa SS, et al. Cutaneous soft tissue sarcoma incidence patterns in the U.S.: an analysis of 12,114 cases. Cancer. 2008;113:616–627.
   PubMed Web of Science ®Google Scholar
• Mendenhall WM, Mendenhall CM, Werning JW, et al. Cutaneous angiosarcoma. Am J Clin Oncol. 2006;29:524–528.
   PubMed Web of Science ®Google Scholar
• Sinnamon AJ, Neuwirth MG, McMillan MT, et al. A prognostic model for resectable soft tissue and cutaneous angiosarcoma. J Surg Oncol. 2016;114:557–563.
   PubMed Web of Science ®Google Scholar
• Young RJ, Brown NJ, Reed MW, et al. Angiosarcoma. Lancet Oncol. 2010;11:983–991.
   PubMed Web of Science ®Google Scholar
• Depla AL, Scharloo-Karels CH, de Jong MA, et al. Treatment and prognostic factors of radiation-associated angiosarcoma (RAAS) after primary breast cancer: a systematic review. Eur J Cancer. 2014;50:1779–1788.
   PubMed Web of Science ®Google Scholar
• Ghareeb ER, Bhargava R, Vargo JA, et al. Primary and radiation-induced breast angiosarcoma: clinicopathologic predictors of outcomes and the impact of adjuvant radiation therapy. Am J Clin Oncol. 2014;39:463–467.
   Web of Science ®Google Scholar
• Yap J, Chuba PJ, Thomas R, et al. Sarcoma as a second malignancy after treatment for breast cancer. Int J Radiat Oncol Biol Phys. 2002;52:1231–1237.
   PubMed Web of Science ®Google Scholar
• Abraham JA, Hornicek FJ, Kaufman AM, et al. Treatment and outcome of 82 patients with angiosarcoma. Ann Surg Oncol. 2007;14:1953–1967.
   PubMed Web of Science ®Google Scholar
• Buehler D, Rice SR, Moody JS, et al. Angiosarcoma outcomes and prognostic factors: a 25-year single institution experience. Am J Clin Oncol. 2014;37:473–479.
   PubMed Web of Science ®Google Scholar
• Espat NJ, Lewis JJ, Woodruff JM, et al. Confirmed angiosarcoma: prognostic factors and outcome in 50 prospectively followed patients. Sarcoma. 2000;4:173–177.
   PubMedGoogle Scholar
• Fayette J, Martin E, Piperno-Neumann S, et al. Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. Ann Oncol. 2007;18:2030–2036.
   PubMed Web of Science ®Google Scholar
• Fury MG, Antonescu CR, Van Zee KJ, et al. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J. 2005;11:241–247.
   PubMed Web of Science ®Google Scholar
• Mark RJ, Poen JC, Tran LM, et al. Angiosarcoma. A report of 67 patients and a review of the literature. Cancer. 1996;77:2400–2406.
   PubMed Web of Science ®Google Scholar
• Italiano A, Cioffi A, Penel N, et al. Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. Cancer. 2012;118:3330–3336.
   PubMed Web of Science ®Google Scholar
• Penel N, Bui BN, Bay JO, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008;26:5269–5274.
   PubMed Web of Science ®Google Scholar
• Singla S, Papavasiliou P, Powers B, et al. Challenges in the treatment of angiosarcoma: a single institution experience. Am J Surg. 2014;208:254–259.
   PubMed Web of Science ®Google Scholar
• Hillenbrand T, Menge F, Hohenberger P, et al. Primary and secondary angiosarcomas: a comparative single-center analysis. Clin Sarcoma Res. 2015;5:14–15.
   PubMedGoogle Scholar
• Scott MT, Portnow LH, Morris CG, et al. Radiation therapy for angiosarcoma: the 35-year University of Florida experience. Am J Clin Oncol. 2013;36:174–180.
   PubMed Web of Science ®Google Scholar
• Behjati S, Gundem G, Wedge DC, et al. Mutational signatures of ionizing radiation in second malignancies. Nat Commun. 2016;7:12605.
   PubMed Web of Science ®Google Scholar
• Smith TL, Morris CG, Mendenhall NP. Angiosarcoma after breast-conserving therapy: long-term disease control and late effects with hyperfractionated accelerated re-irradiation (HART). Acta Oncol. 2014;53:235–241.
   PubMed Web of Science ®Google Scholar